Abstract
Inflammation is part of the normal host response to infection and injury. However, inappropriate inflammation contributes to several diseases, including inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). Both conditions are characterized by the excessive production of inflammatory cytokines, arachidonic acid (AA)-derived eicosanoids, and other inflammatory agents (e.g., reactive oxygen species, adhesion molecules). By virtue of their antiinflammatory action, ω-3 polyunsaturated fatty acids (PUFA) may be beneficial in inflammatory diseases. A large body of evidence supports a protective effect of ω-3 PUFA in experimental animal and ex-vivo models of Crohns disease (CD), Ulcerative colitis (UC) and RA. Although fish oil supplementation in patients with IBD results in ω-3 PUFA incorporation into gut mucosal tissue and modification of inflammatory mediator profiles, the evidence of clinical benefits of ω-3 PUFA is weak. On the other hand, more convincing data support the efficacy of ω-3 PUFA in reducing pain, number of tender joints, duration of morning stiffness, use of non-steroidal anti-inflammatory drugs and improving physical performance in RA patients. In both IBD and RA further clinical trials with large sample size are needed to clarify the efficacy of ω-3 PUFA as a treatment.
Keywords: Polyunsaturated fatty acids, inflammation, reumathoid arthritis, inflammatory bowel disease, Crohn disease, Ulcerative colitis
Current Pharmaceutical Design
Title: Ω-3 Polyunsaturated Fatty Acids and Immune-Mediated Diseases: Inflammatory Bowel Disease and Rheumatoid Arthritis
Volume: 15 Issue: 36
Author(s): C. Ruggiero, F. Lattanzio, F. Lauretani, B. Gasperini, C. Andres-Lacueva and A. Cherubini
Affiliation:
Keywords: Polyunsaturated fatty acids, inflammation, reumathoid arthritis, inflammatory bowel disease, Crohn disease, Ulcerative colitis
Abstract: Inflammation is part of the normal host response to infection and injury. However, inappropriate inflammation contributes to several diseases, including inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). Both conditions are characterized by the excessive production of inflammatory cytokines, arachidonic acid (AA)-derived eicosanoids, and other inflammatory agents (e.g., reactive oxygen species, adhesion molecules). By virtue of their antiinflammatory action, ω-3 polyunsaturated fatty acids (PUFA) may be beneficial in inflammatory diseases. A large body of evidence supports a protective effect of ω-3 PUFA in experimental animal and ex-vivo models of Crohns disease (CD), Ulcerative colitis (UC) and RA. Although fish oil supplementation in patients with IBD results in ω-3 PUFA incorporation into gut mucosal tissue and modification of inflammatory mediator profiles, the evidence of clinical benefits of ω-3 PUFA is weak. On the other hand, more convincing data support the efficacy of ω-3 PUFA in reducing pain, number of tender joints, duration of morning stiffness, use of non-steroidal anti-inflammatory drugs and improving physical performance in RA patients. In both IBD and RA further clinical trials with large sample size are needed to clarify the efficacy of ω-3 PUFA as a treatment.
Export Options
About this article
Cite this article as:
Ruggiero C., Lattanzio F., Lauretani F., Gasperini B., Andres-Lacueva C. and Cherubini A., Ω-3 Polyunsaturated Fatty Acids and Immune-Mediated Diseases: Inflammatory Bowel Disease and Rheumatoid Arthritis, Current Pharmaceutical Design 2009; 15 (36) . https://dx.doi.org/10.2174/138161209789909746
DOI https://dx.doi.org/10.2174/138161209789909746 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacophore Identification for Sigma-1 (σ1) Receptor Binding: Application of the "Deconstruction - Reconstruction - Elaboration" Approach
Mini-Reviews in Medicinal Chemistry Multimodality Imaging of CXCR4 in Cancer: Current Status towards Clinical Translation
Current Molecular Medicine Cardiovascular Disease in Systemic Lupus Erythematosus: The Role of Traditional and Lupus Related Risk Factors
Current Cardiology Reviews Human Papilloma Virus Vaccine Associated Uveitis
Current Drug Safety Molecular and Cellular Pathways as Treatment Targets for Biologic Therapies in Systemic Sclerosis
Current Medicinal Chemistry Association of Serum and Crevicular Fluid Dickkopf-1 Levels with Disease Activity and Periodontitis in Patients with Early Rheumatoid Arthritis
Current Rheumatology Reviews Pregnancy-Specific β1-Glycoproteins: Combined Biomarker Roles, Structure/Function Relationships and Implications for Drug Design
Current Medicinal Chemistry Identification of Expressed miRNAs in Human Rheumatoid Arthritis Using Computational Approach – Discovery of a New miR-7167 from Human
MicroRNA Polymeric Materials and Formulation Technologies for Modified-Release Tablet Development
Mini-Reviews in Medicinal Chemistry Pivotal Roles of Interleukin-17 as the Epicenter of Bone Loss Diseases
Current Pharmaceutical Design KTS and RTS-Disintegrins: Anti-Angiogenic Viper Venom Peptides Specifically Targeting the α1β 1 Integrin
Current Pharmaceutical Design Synthesis of Methotrexate Loaded Chitosan Nanoparticles and in vitro Evaluation of the Potential in Treatment of Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Characterization of Substituted Phenylpropylamides as Highly Selective Agonists at the Melatonin MT2 Receptor
Current Medicinal Chemistry LFA-1 as a Key Regulator of Immune Function: Approaches toward the Development of LFA-1-Based Therapeutics
Current Pharmaceutical Design Nutraceuticals and Bio-inspired Materials from Microalgae and their Future Perspectives
Current Topics in Medicinal Chemistry Type 3 Diabetes Mellitus: A Novel Implication of Alzheimers Disease
Current Topics in Medicinal Chemistry Complement System in SLE as a Target for Antibodies
Current Rheumatology Reviews Atherosclerotic Plaque Stabilization - Potential Role for Immunomodulatory Therapy
Vascular Disease Prevention (Discontinued) Anti-inflammatory Activities of Phenoxyphenyl Ureas Mediated by Inhibition of p38 Kinase
Current Enzyme Inhibition Pharmacophore-Based Discovery of New Human Dihydroorotate Dehydrogenase Inhibitor
Medicinal Chemistry